High Evidence
Research Overview
Orforglipron Research for Obesity
An evidence-based overview of research examining Orforglipron in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Orforglipron produced weight loss in Phase 3 obesity trials. ATTAIN-1 reported 11.2% mean weight reduction at 72 weeks with its highest studied strength versus 2.1% with placebo in 3,127 adults with obesity. These trials do not establish equivalence to injectable agents.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.